A concerning shift in medication patterns may signal inadequate therapeutic options for veterans struggling with post-injury cognitive symptoms. Analysis of nearly one million veterans reveals that CNS stimulant prescribing has more than doubled following traumatic brain injury, despite clinical guidelines advising against this practice. The escalation appears particularly pronounced during the COVID-19 pandemic, when stimulant use reached 194 per 10,000 veterans compared to 83 per 10,000 during the Iraq and Afghanistan combat years. Veterans with concurrent opioid use disorders showed even steeper increases, with stimulant prescribing climbing to 457 per 10,000 by the pandemic period. These medications—typically prescribed for ADHD—are being used off-label because TBI symptoms often mirror attention and concentration difficulties. The data suggests clinicians may be reaching for familiar pharmaceutical tools when evidence-based TBI treatments prove insufficient. This prescribing pattern raises significant questions about treatment protocols for the estimated 400,000 veterans who sustained brain injuries during recent conflicts. The overlap between TBI cognitive symptoms and ADHD creates a diagnostic gray zone where stimulants become an attractive but potentially inappropriate intervention. While these medications can temporarily improve focus and alertness, their long-term effects on brain injury recovery remain poorly understood. The trend also highlights gaps in specialized TBI care within the VA system, potentially forcing providers toward expedient pharmacological solutions rather than comprehensive rehabilitation approaches that address the complex neurological aftermath of brain trauma.